Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

The acquisition of Ambry Genetics will fall under this segment. Ambry generates vast amounts of data across the ~400k patients it sequences each year. Tempus can leverage this data to augment its ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Artificial Intelligence (AI)-based healthcare solutions company Tempus AI TEM has continued to capture investors’ attention despite reporting weaker-than-expected fourth-quarter 2024 results on Feb.

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics (“Ambry”), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...